Over the past three years, the European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) consortium have made significant strides to prepare the European Union for the implementation of the Regulation on Health Technology Assessment (HTA). EUnetHTA 21 has officially concluded its operations, and the HTA Coordination Group will now oversee the Regulation’s implementation.
This partnership began in 2010, with the aim of improving patient access to medicines through collaboration between regulators and HTAs. The dialogue achieved the following milestones:
- Joint Scientific Consultations
- Advanced Therapy Medicinal Products in Oncology
- Patient and Healthcare Professional Training
- Optimizing Assessment Reports
This joint journey has not only improved the regulatory and research environment but also emphasized patient-centred healthcare decisions. With the HTA Coordination Group in charge, the legacy of this partnership will continue to be EU healthcare policy. The partnership has also laid a solid foundation for health technology research legislation and promises a bright future for European health policy.
More information on the achievements is available in EMA technical report and EMA communication here.
